A genetic inference on cancer immune responsiveness

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 520-525

  Wang, Ena ^a   Uccellini, Lorenzo ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer genetics; Cancer microenvironment; Immune responsiveness; Immunotherapy; Melanoma

Indexed keywords

ARTICLE; AUTOIMMUNITY; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENOTYPE; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; METASTASIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

EID: 84862315687     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19531     Document Type: Article

References (30)

1. Salk J. Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 1969; 164:365-80; http://dx.doi.org/10.1111/j.1749-6632.1969.tb14051.x
2. Wang E, Marincola FM. Bottom up: a modular view of immunology. Immunity 2008; 29:9-11; http://dx.doi.org/10.1016/j.immuni.2008.07.002
3. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15:479-86; http://dx.doi.org/10.1016/S0952-7915(03)00103-1
4. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29:256-62; http://dx.doi.org/10 1016/j.it.2008.03.002
5. Immunologic Signatures of Rejection. New York, NY: Springer, 2010.
6. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, et al. Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011; 9:174; http://dx.doi.org/101186/1479-5876-9-174
7. Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, et al. An immunologic portrait of cancer. J Transl Med 2011; 9:146; http://dx.doi.org/10.1186/1479-5876-9-146
8. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; http://dx.doi.org/10.1038/onc.2009.416
9. Louahed J, Grusell O, Gaulis S, et al. Expression of defined genes indentifed by pre-treatment tumor profiling: association with clinical response to GSK MAGE A-3 immunetherapeutic in metastatic melanoma patients. J Clin Oncol 2008; 26:A9045.
10. Weiss G, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011; 17:7440-50; http://dx.doi.org/10.1158/1078-0432.CCR-11-1650
11. Cochran AJ. Histology and prognosis in malignant melanoma. J Pathol 1969; 97:459-68; http://dx.doi.org/10.1002/path.1710970305
12. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; http://dx.doi.org/10.1186/1479-5876-10-1
13. Ascierto ML, Kmieciak M, Idowo MO, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; http://dx.doi.org/10.1007/s10549-011-1470-x
14. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581-6
15. Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000; 21:619-23; http://dx.doi.org/10.1016/S0167-5699(00)01724-2
16. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonmediated rejection genes. Int J Cancer 2011. Epub ahead of press. http://dx.doi.org/10.1002/ijc.26471
17. Wang E, Marincola FM. From the "delayed allergy reaction" to the "immunologic constant of rejection". In: Wang E, Marincola FM, eds. Immunologic Signatures of Rejection. New York, NY: Springer, 2010:3-8.
18. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007; 8:R8; http://dx.doi.org/10.1186/gb-2007-8-1-r8
19. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, et al. Gene expression profiling of cutaneous wound healing. J Transl Med 2007; 5:11; http://dx.doi.org/10.1186/1479-5876-5-11
20. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009; 10:301; http://dx.doi.org/10.1186/1471-2164-10-301
21. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010; 9:555-65; http://dx.doi.org/10.1586/erv.10.55
22. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477-82
23. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-18; http://dx.doi.org/10.1056/NEJMoa053007
24. Chan C, O'Day J. Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 2001; 29:235-8; http://dx.doi.org/10.1046/j.1442-9071.2001.00425.x
25. Maire C, Vercambre-Darras S, Devos P, D'Herbomez M, Dubucquoi S, Mortier L. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. J Eur Acad Dermatol Venereol 2011; http://dx.doi.org/10.1111/j.1468-3083.2011.04364.x
26. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9:277-86; http://dx.doi.org/10.1111/j.1610-0387.2010.07568.x
27. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFNalpha in systemic lupus erythematosus. Science 2001; 294:1540-3; http://dx.doi.org/10.1126/science.1064890
28. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18:676-82; http://dx.doi.org/10.1016/j.coi.2006.09.014
29. Wang E, Zhao Y, Monaco A et al. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. Submitted 2012.
30. Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008; 57:685-91; http://dx.doi.org/10.1007/s00262-007-0407-z